Mobile Advanced Multi-Parameter Reporting in Patients Wearing a Novel Device: Utilization During Cardiac Rehabilitation

Study Overview
=================
Brief Summary
-----------------
Advanced remote multi-parameter reporting during cardiac rehabilitation (MAPS-III). The primary purpose of this observational study is to collect baseline information of cardiac rehabilitation usage in the US for post-myocardial infarction (MI) patients with EF > 35% while wearing the ZOLL AMS device for 30 to 60 days. Secondary data on biometrics, arrhythmias, symptoms, and healthcare utilization will provide additional background information on this population during the early post-MI cardiac rehabilitation period.

Detailed Description
-----------------
To collect baseline data on cardiac rehabilitation usage (referrals and completion) in recent post-MI patients with EF > 35%.To collect data on AMS-derived biometric data (e.g. HR, activity) and arrhythmias, and subject-reported symptoms, beta blocker/ivabradine usage (dose/changes) and cardiovascular events. The participating centers will enroll consenting subjects in a sequential manner to avoid preferential selection of patients to participate in the study. Subjects will be consented by the center study staff, and if eligible will wear the FDA-cleared AMS device for 30-60 days. Subject demographic information and clinical history will be obtained at the time of enrollment. During the study period, the prescribing physician-investigator will be blinded to AMS data. Final subject follow-up will be at 3 months. A sample size of 150 subjects is estimated in order to have 100 subjects with at least 30 days of AMS use for analysis.

Official Title
-----------------
Mobile Advanced Multi-Parameter Reporting in Patients Wearing a Novel Device: Utilization During Cardiac Rehabilitation

Conditions
-----------------
Heart Attack, Cardiac Event, Cardiac Disease, Cardiac Infarct, NSTEMI, STEMI

Intervention / Treatment
-----------------
* Device: ZOLL Arrhythmia Management System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Both male and female subjects who are between 21 - 75 years of age, inclusively Subjects who are consented and enrolled into the study prior to discharge from the qualifying acute myocardial infarction Subjects with a consistent EF >35% post the qualifying acute myocardial infarction Exclusion Criteria Subjects with an implantable cardiac device such as left ventricular assistive device, pacemaker, an implanted cardioverter defibrillator (ICD), a cardiac resynchronization therapy device, subcutaneous ICDs, pressure monitors, and loop monitors. Subjects with wearable cardioverter defibrillator, Holter monitors, wearable event recorders, and other mobile cardiac telemetry devices at the same time. Subjects with a skin condition preventing them from wearing the AMS device. Subjects who are non-ambulatory for any reason. Subjects who are self-reporting to be pregnant. Subjects with comorbidities that would preclude adherence to a cardiac rehabilitation program - at the discretion of the physician. Subjects participating or planning to participate in another interventional study during the protocol-defined study period

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Treatment<br>Subjects assigned to wear the FDA-cleared AMS device for 30-60 days Sequential enrollment to avoid preferential selection Investigator blinded to the AMS data | Device: ZOLL Arrhythmia Management System<br>* AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity, and body posture (biometric data)<br>* Other names: AMS;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac rehabilitation program referrals and completions (in-clinic or home-based) | Measure the completion rate of patients undergoing cardiac rehabilitation programs i.e. the number of cardiac rehabilitation program referrals vs. number of cardiac rehabilitation program completions | 30-60 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AMS-derived data - Heart Rate | Improvement in nighttime resting heart rate | 30-60 days | 
| AMS-derived data - Activity | Changes in total daily activity as detected by the AMS accelerometers | 30-60 days | 
| AMS-derived data - Arrhythmias | Occurrence of Arrhythmias as detected by the AMS | 30-60 days | 
| Subject reported outcomes - Beta blocker/ivabradine usage/changes | Initiation/Termination/Changes in beta blocker/ivabradine usage recorded via weekly diary | 30-60 days | 
| Subject reported outcomes - Symptoms | Occurrence and changes in symptoms recorded via weekly diary | 30-60 days | 
| Subject reported outcomes - Cardiovascular events | Cardiovascular events as measured by health care use i.e. unplanned health care provider visits due to cardiovascular event, recorded via weekly diary | 30-60 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
heart attack, myocardial infarction, STEMI, NSTEMI